This multi-institutional trial has been completed and data is being assessed to determine the clinical efficacy of oral 2-CdA, confirm selective lymphocyte and monocyte depletion and further characterize the effects of 2CdA on biochemical and phenotypic surrogate endpoints of rheumatoid arthitis disease activity.
Showing the most recent 10 out of 570 publications